Published in Virology on January 19, 2010
The Antibody Response against HIV-1. Cold Spring Harb Perspect Med (2012) 1.65
The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol (2010) 1.49
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol (2012) 1.44
Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med (2014) 1.19
Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog (2013) 1.05
Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol (2013) 0.91
Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine (2012) 0.89
HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. EBioMedicine (2015) 0.88
Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol (2014) 0.88
Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. J Virol (2015) 0.79
In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies. PLoS One (2011) 0.78
Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. PLoS Pathog (2016) 0.75
The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol (1987) 266.90
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol (1980) 113.75
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science (1993) 3.62
Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 3.57
Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med (1999) 3.11
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol (2006) 2.95
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol (1991) 2.84
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol (2001) 2.53
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 2.45
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol (2006) 2.41
Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog (2009) 2.29
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol (2001) 2.24
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol (2008) 1.80
Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol (2001) 1.66
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol (2006) 1.59
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol (2003) 1.51
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A (2007) 1.50
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses (1994) 1.47
Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol (2009) 1.24
Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res (2007) 1.19
Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines. J Virol (1993) 1.15
Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS (1990) 1.04
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J Virol (2005) 1.01
Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis (2007) 4.12
HIV vaccine research: the way forward. Science (2008) 3.86
HIV/AIDS in women: an expanding epidemic. Science (2005) 3.68
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS (2008) 3.42
Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS (2007) 3.14
HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis (2006) 3.09
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol (2006) 2.95
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 2.45
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr (2007) 2.34
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J (2004) 2.30
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr (2009) 2.26
Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis (2009) 2.24
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis (2003) 2.10
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS (2009) 1.87
Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol (2002) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis (2007) 1.75
Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis (2004) 1.74
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol (2003) 1.72
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
Association between cervical shedding of herpes simplex virus and HIV-1. AIDS (2002) 1.64
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64
Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis (2004) 1.61
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med (2008) 1.60
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis (2009) 1.57
HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS (2015) 1.55
Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS (2004) 1.55
Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (2008) 1.55
HIV‐exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV‐dependent host factors. J Infect Dis (2010) 1.54
Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res (2003) 1.52
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med (2011) 1.51
Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. MBio (2013) 1.50
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
Risk compensation following male circumcision: results from a two-year prospective cohort study of recently circumcised and uncircumcised men in Nyanza Province, Kenya. AIDS Behav (2014) 1.43
Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS (2004) 1.38
Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis (2003) 1.36
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One (2009) 1.35
Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection. AIDS Res Hum Retroviruses (2008) 1.34
Basic statistical considerations in virological experiments. J Virol (2005) 1.32
The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS (2004) 1.32
Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis (2004) 1.31
Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 1.28
Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS (2007) 1.28
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS (2005) 1.27
Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS (2010) 1.25
Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol (2009) 1.24
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis (2010) 1.22
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses (2006) 1.21
Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS (2009) 1.21
Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res (2007) 1.19
Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis (2002) 1.19
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J Clin Microbiol (2006) 1.17
A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol (2006) 1.17
Multiplex detection of bacteria associated with normal microbiota and with bacterial vaginosis in vaginal swabs by use of oligonucleotide-coupled fluorescent microspheres. J Clin Microbiol (2009) 1.16
Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr (2008) 1.16
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One (2008) 1.15
Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol (2007) 1.15
Subtype C Is associated with increased vaginal shedding of HIV-1. J Infect Dis (2005) 1.14
Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr (2009) 1.14
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog (2012) 1.14
The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol (2011) 1.13
Molecular definition of vaginal microbiota in East African commercial sex workers. Appl Environ Microbiol (2011) 1.13
Associations between intravaginal practices and bacterial vaginosis in Kenyan female sex workers without symptoms of vaginal infections. Sex Transm Dis (2007) 1.12
Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial. J Acquir Immune Defic Syndr (2004) 1.12
HIV-1 superinfection and its implications for vaccine design. Curr HIV Res (2010) 1.11
HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS (2009) 1.11
Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS (2004) 1.11
Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation. J Acquir Immune Defic Syndr (2012) 1.09
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses (2006) 1.09